A better Alzheimer’s drug?

Social media announcement of PAC-832, a claimed novel Alzheimer's drug candidate

A post on X (formerly Twitter) announcing the invention of a new drug called PAC-832, described as the world's first selective GalR1 antagon

https://doi.org/10.1126/science.aeb6987

Why Has There Been So Little Progress on Alzheimer's Disease?

Monash University study finds copper-delivering drug Cu(ATSM) reduces Alzheimer's proteins and improves memory in lab tests

Monash University researchers have discovered that a copper-delivering drug called Cu(ATSM) significantly reduces toxic Alzheimer's proteins

The costly failure of amyloid-beta drugs: A cautionary tale in pharmaceutical development

The article discusses drug classes that are perceived as failures after massive investment and clinical trials, using amyloid-beta drugs for

Novel Blood-Brain Barrier Modulation Strategy Shows Promise for Alzheimer's Treatment Through Enhanced Amyloid-β Clearance

This scientific research presents a novel therapeutic approach for Alzheimer's disease that targets the blood-brain barrier (BBB) to enhance